Ný lyf fyrir hrörnun í augnbotnum og skylda sjúkdóma

Einar Stefánsson; Morten la Cour; Gudleif Helgadóttir; Haraldur Sigurdsson; Fridbert Jónasson

Ný lyf fyrir hrörnun í augnbotnum og skylda sjúkdóma

Einar Stefánsson, Morten la Cour, Gudleif Helgadóttir, Haraldur Sigurdsson, Fridbert Jónasson

Abstract

New drugs for age-related macular degeneration present a major advance in the treatment of the most common cause of blindness in Iceland. Vascular endothelial growth factor antibodies reduce the risk of blindness and improve vision in patients with age-related macular degeneration.

Bidragets oversatte titel	New drug treatment for age-related macular degeneration
Originalsprog	Islandsk
Tidsskrift	Laeknabladid
Vol/bind	93
Udgave nummer	4
Sider (fra-til)	299-301
Antal sider	3
ISSN	0023-7213
Status	Udgivet - apr. 2007
Udgivet eksternt	Ja

Emneord

Angiogenesis Inhibitors/administration & dosage
Antibodies, Monoclonal/administration & dosage
Antibodies, Monoclonal, Humanized
Bevacizumab
Humans
Injections/methods
Macular Degeneration/drug therapy
Ranibizumab
Vascular Endothelial Growth Factor A/immunology
Vitreous Body

Citationsformater

@article{fff20301e7c941b7902462d945976ff7,

title = "N{\'y} lyf fyrir hr{\"o}rnun {\'i} augnbotnum og skylda sj{\'u}kd{\'o}ma",

abstract = "New drugs for age-related macular degeneration present a major advance in the treatment of the most common cause of blindness in Iceland. Vascular endothelial growth factor antibodies reduce the risk of blindness and improve vision in patients with age-related macular degeneration.",

keywords = "Angiogenesis Inhibitors/administration & dosage, Antibodies, Monoclonal/administration & dosage, Antibodies, Monoclonal, Humanized, Bevacizumab, Humans, Injections/methods, Macular Degeneration/drug therapy, Ranibizumab, Vascular Endothelial Growth Factor A/immunology, Vitreous Body",

author = "Einar Stef{\'a}nsson and {la Cour}, Morten and Gudleif Helgad{\'o}ttir and Haraldur Sigurdsson and Fridbert J{\'o}nasson",

year = "2007",

month = apr,

language = "Islandsk",

volume = "93",

pages = "299--301",

journal = "Laeknabladid",

issn = "0023-7213",

publisher = "Icelandic Medical Association",

number = "4",

}

TY - JOUR

T1 - Ný lyf fyrir hrörnun í augnbotnum og skylda sjúkdóma

AU - Stefánsson, Einar

AU - la Cour, Morten

AU - Helgadóttir, Gudleif

AU - Sigurdsson, Haraldur

AU - Jónasson, Fridbert

PY - 2007/4

Y1 - 2007/4

N2 - New drugs for age-related macular degeneration present a major advance in the treatment of the most common cause of blindness in Iceland. Vascular endothelial growth factor antibodies reduce the risk of blindness and improve vision in patients with age-related macular degeneration.

AB - New drugs for age-related macular degeneration present a major advance in the treatment of the most common cause of blindness in Iceland. Vascular endothelial growth factor antibodies reduce the risk of blindness and improve vision in patients with age-related macular degeneration.

KW - Angiogenesis Inhibitors/administration & dosage

KW - Antibodies, Monoclonal/administration & dosage

KW - Antibodies, Monoclonal, Humanized

KW - Bevacizumab

KW - Humans

KW - Injections/methods

KW - Macular Degeneration/drug therapy

KW - Ranibizumab

KW - Vascular Endothelial Growth Factor A/immunology

KW - Vitreous Body

M3 - Tidsskriftartikel

C2 - 17460341

SN - 0023-7213

VL - 93

SP - 299

EP - 301

JO - Laeknabladid

JF - Laeknabladid

IS - 4

ER -

Ný lyf fyrir hrörnun í augnbotnum og skylda sjúkdóma

Abstract

Emneord

Fingeraftryk

Citationsformater